RDY 478 (Zolpidem 5 mg)
Pill with imprint RDY 478 is Pink, Elliptical / Oval and has been identified as Zolpidem tartrate 5 mg. It is supplied by Dr. Reddy’s Laboratories Inc..
Zolpidem is used in the treatment of insomnia and belongs to the drug class miscellaneous anxiolytics, sedatives and hypnotics. Risk cannot be ruled out during pregnancy. Zolpidem 5 mg is classified as a Schedule 4 controlled substance under the Controlled Substance Act (CSA).
Images for RDY 478
Zolpidem tartrate
- Imprint:
- RDY 478
- Strength:
- 5 mg
- Color:
- Pink
- Size:
- 3.00 mm
- Shape:
- Elliptical / Oval
- Availability:
- Prescription only
- Drug Class:
- Miscellaneous anxiolytics, sedatives and hypnotics
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- 4 - Some potential for abuse
- Labeler / Supplier:
- Dr. Reddy’s Laboratories Inc.
- Inactive Ingredients:
- silicon dioxide
hypromelloses
lactose monohydrate
magnesium stearate
microcrystalline cellulose
polyethylene glycol
sodium starch glycolate type A potato
titanium dioxide
Note: Inactive ingredients may vary.
More about zolpidem
- Zolpidem Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- En Español
- 721 Reviews
- Drug class: miscellaneous anxiolytics, sedatives and hypnotics
Consumer resources
- Zolpidem
- Zolpidem Extended-Release Tablets
- Zolpidem Sublingual Tablets (Edluar)
- Zolpidem Oral Spray
- Zolpidem Sublingual Tablets (Intermezzo)
- ... +3 more
Other brands: Ambien, Ambien CR, Zolpimist, Intermezzo, Edluar
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2018 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
